Spironolactone, Mood, Depression, and Anxiety: What Is Known

Editorial evidence status: This page was reconciled to current U.S. labeling, the 2024 AAD acne guideline, the SAFA randomized trial, and a meta-analysis of acne and mental health on August 29, 2026. Medical review is pending. It does not diagnose a psychiatric condition or tell a patient to stop, restart, or change spironolactone independently.

Start With What the Label Actually Says

Spironolactone's current U.S. label groups lethargy, mental confusion, ataxia, dizziness, headache, and drowsiness under “nervous system/psychiatric” adverse reactions [1]. The same section says these reactions came from clinical trials or postmarketing reports and that the population size, frequency, and causal relationship cannot always be established.

That wording supports several conclusions:

• confusion and drowsiness are real labeled signals worth taking seriously;
• the label does not provide an acne-specific percentage for them;
• the label does not list a controlled depression or anxiety incidence; and
• a postmarketing report is not proof that the drug caused every reported event.

The previous article claimed 5% to 10% mood-event rates, a 7.2% registry rate, dose-specific libido percentages, and a predictable six- to twelve-week psychiatric-risk window. The cited destinations did not establish those claims.

Mood Claim-to-Evidence Map

What the SAFA Trial Adds

The SAFA trial randomized 410 adult women with persistent facial acne to spironolactone or placebo. Participants assigned to spironolactone took 50 mg daily through week six and could increase to 100 mg daily through week 24. Acne-specific quality-of-life scores favored spironolactone, with a larger difference at week 24 than week 12 [3].

Adverse reactions were similar overall, although headache was more common with spironolactone. No serious adverse reactions were reported. That is useful reassurance for the studied population and regimen.

But Acne-QoL is not the same as a structured depression or anxiety diagnosis. SAFA should not be cited as proof that spironolactone is antidepressant, anxiolytic, or psychiatrically neutral in every patient. It also should not be transformed into a universal dose-escalation instruction.

Acne Can Be Part of the Mood Picture

A meta-analysis of 42 studies found associations between acne and both depression and anxiety [4]. The studies differed in populations, settings, and outcome measurement, so the pooled result does not predict one person's symptoms. It does show why attribution is difficult: mood may change because acne is worsening, improving, or affecting social life, even when a medicine has no direct psychiatric effect.

When mood changes during treatment, at least four timelines deserve attention:

1. the acne trajectory;
2. the spironolactone start and dose-change dates;
3. other medication, hormone, sleep, or substance changes; and
4. major health or life events.

The goal is not to dismiss a symptom as “just acne” or automatically label it a drug reaction. The goal is to preserve enough context for a clinician to assess both.

Fatigue, Drowsiness, Dizziness, and Depression Can Overlap

Lethargy and drowsiness can feel like low motivation. Dizziness or low blood pressure can reduce activity. Dehydration, hyponatremia, hyperkalemia, kidney dysfunction, or another illness can also produce weakness or cognitive symptoms. None of those possibilities rules out depression.

The label warns that excessive diuresis may cause dehydration, hypotension, and worsening renal function, particularly in susceptible patients. It also identifies electrolyte abnormalities and interactions with medicines that increase potassium [1]. A symptom review may therefore include blood pressure, fluid losses, kidney risk, concomitant medicines, and laboratory testing when clinically appropriate.

This does not justify a universal instruction to increase salt, drink a fixed fluid volume, take magnesium, or order the same laboratory panel on the same day for every acne patient.

Depression and Anxiety: The Evidence Boundary

No current source used for this page supplies a controlled incidence of depression or anxiety caused by spironolactone in women treated for acne. The responsible answer to “Can spironolactone cause depression?” is therefore not a confident yes, no, or percentage.

Instead:

• new or worsening depression should be assessed on its own merits;
• anxiety should not be dismissed because it is absent from a label list;
• the presence of a symptom after a dose change raises a temporal question but does not prove causality; and
• improvement after acne clears may reflect reduced disease burden rather than a direct brain effect of spironolactone.

The old page claimed that spironolactone's supposed GABA effect “would be anxiolytic, not anxiogenic.” That conclusion was removed. Receptor speculation cannot predict a patient's clinical response.

A Reproducible Symptom Timeline

Bring a short record to the prescriber rather than relying on a vague before-and-after memory:

This is an information-gain artifact: it helps separate competing explanations without pretending to diagnose the cause.

Interactions That Can Complicate the Picture

The label says spironolactone reduces renal clearance of lithium and increases lithium-toxicity risk, requiring periodic lithium monitoring when the medicines are used together [1]. Lithium toxicity can include neurologic and cognitive symptoms, so that combination deserves explicit medication reconciliation.

ACE inhibitors, angiotensin-receptor blockers, NSAIDs, trimethoprim, heparin products, potassium supplements, and potassium-containing salt substitutes can also change potassium or kidney risk [1]. These are concrete label-supported interaction questions. The prior page's blanket statement that SSRIs and SNRIs have no clinically meaningful interaction was too broad and has been removed.

Screening Is a Clinical Tool, Not a Mandatory Internet Protocol

PHQ-9 and GAD-7 can support evaluation and follow-up, but the current AAD acne guideline does not mandate that every spironolactone patient complete them at baseline, six weeks, and three months [2]. A page should not invent a score-change threshold that automatically reduces the dose.

Formal screening may be especially useful when symptoms are persistent, function changes, there is a prior psychiatric history, or the patient and clinician need a shared baseline. The response to any score still depends on the individual, the presence of self-harm thoughts, and a full assessment.

When to Seek Help

Contact the prescriber promptly for a new persistent mood change, disabling anxiety, marked drowsiness, confusion, repeated dizziness, faintness, or symptoms that followed a start or dose change. Do not assume hydration alone will fix cognitive or mood symptoms.

Seek urgent or emergency help for suicidal thoughts, inability to stay safe, severe confusion, fainting, a seizure, chest pain, severe weakness, an irregular heartbeat, or another severe new symptom. In the United States, call or text 988 for immediate suicide and crisis support; call emergency services when there is imminent danger.

Bottom Line

Spironolactone labeling contains real nervous-system and psychiatric signals, but it does not provide a depression or anxiety rate for acne treatment. SAFA supports acne effectiveness and better acne-specific quality of life in the studied group; it does not settle every psychiatric-causality question. The highest-quality response to a mood change is a documented timeline, medication and physical-risk review, and appropriate mental-health assessment—not an invented incidence, receptor story, or automatic dosing rule.